POST-MORTEM CHARACTERISTICS OF HEPATIC MICROSOMAL DRUG OXIDIZING ENZYME-SYSTEM

被引：11

作者：

MACLEOD, SM

RENTON, KW

EADE, NR

机构：

[1] MCGILL UNIV,DEPT PHARMACOL & THRAPEUTICS,MONTREAL,QUEBEC,CANADA

[2] MCGILL UNIV,DEPT PEDIAT,MONTREAL,QUEBEC,CANADA

来源：

CHEMICO-BIOLOGICAL INTERACTIONS | 1973年 / 7卷 / 01期

关键词：

D O I：

10.1016/0009-2797(73)90013-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：29 / 37

页数：9

共 19 条

[1]

ACKERMANN E, 1970, Biochemical Pharmacology, V19, P327, DOI 10.1016/0006-2952(70)90190-5

[2]

ALVARES AP, 1969, CLIN PHARMACOL THER, V10, P655

[3]

COCHIN J, 1959, J PHARMACOL EXP THER, V125, P105

[4]

CREAVEN PJ, 1963, BIOCHEM J, V87, pP19

[5] APPARENT MICHAELIS CONSTANTS FOR METABOLISM OF (UREYL-C-14)TOLBUTAMIDE BY HUMAN LIVER MICROSOMAL PREPARATIONS [J].

DARBY, FJ ;

EVANS, DAP ;

GRUNDY, RK .

BIOCHEMICAL PHARMACOLOGY, 1972, 21 (03) :407-&

[6] HUMAN LIVER MICROSOMAL DRUG METABOLISM [J].

DARBY, FJ ;

NEWNES, W ;

EVANS, DAP .

BIOCHEMICAL PHARMACOLOGY, 1970, 19 (04) :1514-&

[7] EFFECT OF DRUG SUBSTRATES ON REDUCTION OF HEPATIC MICROSOMAL CYTOCHROME P-450 BY NADPH [J].

GIGON, PL ;

GRAM, TE ;

GILLETTE, JR .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1968, 31 (04) :558-&

[8]

JONDORF W R, 1970, Research Communications in Chemical Pathology and Pharmacology, V1, P581

[9]

KABAT EA, 1967, EXPTL IMMUNOCHEMISTR

[10]

KATO R, 1965, J PHARMACOL EXP THER, V150, P279

← 1 2 →